GEN Exclusives

More »

GEN News Highlights

Back to Item »

Isis Wins $5M from GSK with Launch of First Phase I Study

ISIS-TTRRx, an antisense product, will be evaluated as a treatment for transthyretin amyloidosis.

Forward this item to a colleague:


(Separate multiple addresses by commas)


(Separate multiple addresses by commas)


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Genetics and Intelligence

Do you believe research on the genetics of intelligence can improve education?

More »